Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
January 21 2013 - 7:20AM
Marketwired
Lost revenues from expiring patents has played a major part in the
Biotech Industry's success in recent years. A total of 676
takeovers of biotechnology and pharmaceutical companies have
occurred in the past three years, with an average premium of 38
percent, according to data collected by Bloomberg. Five Star
Equities examines the outlook for companies in the Biotech Industry
and provides equity research on ImmunoGen, Inc. (NASDAQ: IMGN) and
InterMune, Inc. (NASDAQ: ITMN).
Access to the full company reports can be found at:
www.FiveStarEquities.com/IMGN
www.FiveStarEquities.com/ITMN
At the end of the third quarter five of the biggest drug makers
in the U.S. held over $70 billion in cash, near cash and short-term
investments. Major revenue losses from patent expirations have
forced big pharmaceutical companies to look to biotech companies to
help fill the void. Pfizer's Lipitor and Bristol-Myers' Plavix,
which lost exclusivity in late 2011, had combined annuals revenues
of $17 billion at their peaks.
"We're through many cost-cutting programs, restructurings and
portfolio arrangements," said Henry Gosebruch, Managing Director,
Mergers & Acquisitions J.P. Morgan. "When you put that together
with record levels of cash available and improving, but still
moderate R&D productivity, we think there will be more big
pharma M&A activity in 2013."
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
ImmunoGen develops targeted anticancer therapeutics using its
TAP technology together with the Company's expertise in monoclonal
antibodies and tumor biology. A TAP compound uses a tumor-targeting
monoclonal antibody to deliver one of ImmunoGen's purpose-developed
cancer-killing agents specifically to tumor cells. The company is
scheduled to release its second quarter fiscal 2013 results on
Friday, January 25th.
InterMune is a biotechnology company focused on the research,
development and commercialization of innovative therapies in
pulmonology and orphan fibrotic diseases. The company recently
reported that Esbriet, their treatment for IPF, has launched in
nine of the Company's 15 targeted European countries including the
two largest EU markets, Germany and France.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024